Which antihypertensive class may mask signs of hypoglycemia in diabetic patients?

Study for the WGU NURS6800 D116 Advanced Pharmacology Exam. Use flashcards and multiple-choice questions with hints and explanations. Prepare thoroughly for your exam!

Multiple Choice

Which antihypertensive class may mask signs of hypoglycemia in diabetic patients?

Explanation:
Beta-adrenergic blockade can hide the early warning signs of hypoglycemia in diabetes. When blood glucose drops, the body releases catecholamines that trigger sympathetic symptoms such as tachycardia, tremor, and anxiety to warn the person that something is wrong. Blocking beta receptors blunts these signs, making hypoglycemia harder to recognize. Additionally, beta blockers—especially nonselective ones that block both beta-1 and beta-2 receptors—can impair hepatic glucose production by inhibiting beta-2–mediated glycogenolysis and gluconeogenesis, potentially worsening or prolonging hypoglycemia. Other antihypertensives don’t suppress these adrenergic warning signs to the same extent, so they’re less likely to mask hypoglycemia.

Beta-adrenergic blockade can hide the early warning signs of hypoglycemia in diabetes. When blood glucose drops, the body releases catecholamines that trigger sympathetic symptoms such as tachycardia, tremor, and anxiety to warn the person that something is wrong. Blocking beta receptors blunts these signs, making hypoglycemia harder to recognize. Additionally, beta blockers—especially nonselective ones that block both beta-1 and beta-2 receptors—can impair hepatic glucose production by inhibiting beta-2–mediated glycogenolysis and gluconeogenesis, potentially worsening or prolonging hypoglycemia. Other antihypertensives don’t suppress these adrenergic warning signs to the same extent, so they’re less likely to mask hypoglycemia.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy